Search Results - "Tong, Linjiang"

Dual targeting of VEGFR2 and CSF1R with SYHA1813 confers novel strategy for treating both BRAF wild-type and mutant melanoma.

Authors: Shi, Wenhao Tang, Haotian Tong, Linjiang et al.

Source: Cancer Cell International. 7/25/2025, Vol. 25 Issue 1, p1-12. 12p.

Correction: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Authors: Zhang, Tao Qu, Rong Chan, Shingpan et al.

Source: Molecular Cancer. 8/19/2023, Vol. 22 Issue 1, p1-2. 2p.

Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Authors: Zhang, Tao Qu, Rong Chan, Shingpan et al.

Source: Molecular Cancer. 8/17/2021, Vol. 20 Issue 1, p1-1. 1p.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.

Authors: Zhang, Tao Qu, Rong Chan, Shingpan et al.

Source: Molecular Cancer. 5/13/2020, Vol. 19 Issue 1, p1-15. 15p. 1 Color Photograph, 1 Chart, 5 Graphs.

Discovery of 1,3-Diaryl-pyridones as Potent VEGFR-2 Inhibitors: Design, Synthesis, and Biological Evaluation.

Authors: Yan, Wei Huang, Zhaoru Wang, Zhengyu et al.

Source: Chemical Biology & Drug Design. May2016, Vol. 87 Issue 5, p694-703. 10p.

Synthesis of 7-Triazole-substituted Camptothecin via Click Chemistry and Evaluation of in vitro Antitumor Activity.

Authors: Wang, Lei Yuan, Wei Zhang, Jie et al.

Source: Chinese Journal of Chemistry. Feb2014, Vol. 32 Issue 2, p157-162. 6p.